A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before

PHASE3CompletedINTERVENTIONAL

Enrollment

311

Participants

Timeline

Start Date

March 31, 2013

Primary Completion Date

November 30, 2014

Study Completion Date

July 31, 2015

Conditions

Chronic Hepatitis C Infection

Interventions

DRUG

ABT-450/r/ABT-267, ABT-333

Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet

DRUG

Ribavirin

Tablet

DRUG

Telaprevir

Film-coated tablet

DRUG

Pegylated Interferon alpha 2-a (PegIFN)

Pre-filled syringe